W

bioLLM/wiki

LLM-Synthesized Biotech Database

Live

cytochrome P450 family 2 subfamily C member 19

cytochrome P450 family 2 subfamily C member 19

Overview

Cytochrome P450 family 2 subfamily C member 19 (CYP2C19) is a member of the cytochrome P450 superfamily of drug-metabolizing enzymes. It is best known for its role in hepatic and extrahepatic oxidative metabolism of a range of clinically important compounds, including several proton-pump inhibitor and antiplatelet drug substrates. As a pharmacogenetically variable enzyme, CYP2C19 activity differs substantially between individuals because of inherited polymorphisms that can produce poor, intermediate, normal, rapid, or ultrarapid metabolizer phenotypes.

Clinically, CYP2C19 is important because variation in its function can alter drug exposure, therapeutic response, and adverse-event risk. This is especially relevant for clopidogrel, where CYP2C19-mediated bioactivation influences antiplatelet effect, and for omeprazole and related proton-pump inhibitor drugs, where CYP2C19 contributes to clearance. The enzyme is also a frequent focus of drug-drug interaction studies, because inhibitors or mechanism-based inactivators of CYP2C19 can change the pharmacokinetics of coadministered therapies.

Focus of Latest Publications

Recent publications have focused on cytochrome P450 family 2 subfamily C member 19 (CYP2C19) primarily in the context of drug metabolism, antiplatelet response, and disease-associated expression changes. Several studies examined CYP2C19 genetic variation or functional activity alongside clopidogrel therapy, reflecting its established role in activating this prodrug and influencing treatment response. In patients with recurrent ischemic stroke receiving clopidogrel monotherapy, CYP2C19 intermediate and poor metabolism were significantly associated with clopidogrel resistance when ABCB1 efflux activity was normal, while CYP2C9 also contributed in patients with normal CYP2C19 metabolism. In atrial fibrillation patients undergoing PCI and treated with oral anticoagulation plus clopidogrel, CYP2C19 poor/intermediate metabolizer status was not significantly associated with the primary ischemic outcome, but the study suggested a possible protective effect against bleeding, and platelet reactivity measures were linked to ischemic and bleeding risk.

Other publications addressed CYP2C19 as a pharmacokinetic interaction target. One mechanistic study identified anwuligan, a bioactive compound from nutmeg and Schisandra chinensis, as a mechanism-based inhibitor of CYP2C19. The authors showed that an o-quinone intermediate formed during metabolism was responsible for irreversible enzyme inactivation, and in rats, anwuligan pretreatment increased amitriptyline exposure while reducing nortriptyline exposure, indicating a clinically relevant drug-drug interaction potential. Another study compared cardiovascular events in patients receiving clopidogrel together with proton pump inhibitors classified by CYP2C19 inhibitory potency, reflecting concern that stronger CYP2C19 inhibition may blunt clopidogrel’s antiplatelet effect. A related report in gastroesophageal reflux disease highlighted a high prevalence of CYP2C19 rapid and ultrarapid metabolism, consistent with the idea that CYP2C19 genotype may contribute to inadequate proton pump inhibitor response.

Beyond pharmacogenetics, CYP2C19 was also implicated in disease biology. In a multi-omics study of metabolic dysfunction-associated steatotic liver disease, CYP2C19 was downregulated across disease progression, and overexpression of CYP2C19 in functional assays reduced hepatocellular lipid accumulation, oxidative stress, inflammatory responses, and key lipogenic gene expression. Together, these recent publications portray CYP2C19 as a clinically important determinant of variable drug response and as a potential modulator of metabolic liver disease pathways.

Key Publications

Content is generated using Large Language Models (LLMs) and may contain errors or hallucinations. Experts periodically review it to verify accuracy and maintain database integrity.